Results 21 to 30 of about 28,367 (198)

Comparative safety of bedaquiline and delamanid in patients with multidrug resistant tuberculosis: A nationwide retrospective cohort study

Journal of Microbiology, Immunology and Infection, 2023
Background/Purpose(s): Bedaquiline and delamanid were recently approved for multidrug resistant tuberculosis (MDR-TB). Bedaquiline carries a black box warning of increased risk of death compared to the placebo arm, and there is a need to establish the ...
Ju Hwan Kim, Hyesung Lee, In-Sun Oh, Han Eol Jeong, Sungho Bea, Seung Hun Jang, Hyunjin Son, Ju-Young Shin   +7 more
doaj   +1 more source

Effects of Bedaquiline Combined with Fluoroquinolone and/or Clofazimine on QT Interval in Patients with Multidrug-Resistant Tuberculosis: a Retrospective Study

Microbiology Spectrum, 2023
With the application of bedaquiline (Bdq), the success rate of multidrug-resistant tuberculosis (MDR-TB) treatment has been significantly improved; however, the cardiac safety of the patients during treatment cannot be ignored. Hence, this study compared
Rong Li, Jin-Bao Ma, Hong Yang, Han Yang, Xin-Jun Yang, Yan-Qin Wu, Fei Ren   +6 more
doaj   +1 more source

In Vitro Bedaquiline and Clofazimine Susceptibility Testing in Mycobacterium abscessus

, 2022
Bedaquiline and clofazimine are increasingly used to treat infections with Mycobacterium abscessus. We determined distributions of MICs by broth microdilution for bedaquiline and clofazimine for 61 M. abscessus clinical isolates using different media and
Akdoğan Kittana, Fatma Nur, Schulthess, Bettina, Hömke, Rico, Sander, Peter   +3 more
core   +2 more sources

Emergence of bedaquiline resistance in a high tuberculosis burden country

, 2022
Rationale: Bedaquiline has been classified as a group A drug for the treatment of multidrug-resistant tuberculosis (MDR-TB) by the World Health Organization; however, globally emerging resistance threatens the effectivity of novel MDR-TB treatment ...
Barilar, Ivan,, Crudu, Valeriu,, Utpatel, Christian, Andres, Sönke,, Maurer, Florian P., Crudu, Valeriu, Chesov, Dumitru, Heyckendorf, Jan,, Reimann, Maja, Lange, Christoph, Niemann, Stefan,, Lange, Christoph,, Donica, Ana, Maurer, Florian P.,, Chesov, Dumitru,, Reimann, Maja,, Donica, Ana,, Chesov, Elena, Utpatel, Christian,, Andres, Sönke, Barilar, Ivan, Niemann, Stefan, Merker, Matthias, Heyckendorf, Jan, Merker, Matthias,, Chesov, Elena,   +25 more
core   +1 more source

Bedaquiline exposure in pregnancy and breastfeeding in women with rifampicin-resistant tuberculosis [PDF]

, 2022
Aims: We aimed to explore the effect of pregnancy on bedaquiline pharmacokinetics (PK) and describe bedaquiline exposure in the breast milk of mothers treated for rifampicin-resistant tuberculosis (TB), where there are no human data available.
Loveday, M, McIlleron, Helen, Mkhize, Buyisile, McIlleron, H, Paolo Denti, Gausi, Kamunkhwala, Helen McIlleron, Marian Loveday, Denti, P, Catriona Waitt, Maartens, G, Wiesner, Lubbe, Kamunkhwala Gausi, Richard Court, Maartens, Gary, Loveday, Marian, Lubbe Wiesner, Gary Maartens, Mkhize, B, Waitt, Catriona, Denti, Paolo, Buyisile Mkhize, Court, R, Waitt, C, Court, Richard, Gausi, K, Wiesner, L   +26 more
core   +1 more source

A regimen containing bedaquiline and delamanid compared to bedaquiline in patients with drug-resistant tuberculosis. [PDF]

, 2019
There are limited data on combining delamanid and bedaquiline in drug-resistant tuberculosis (DR-TB) regimens. Prospective long-term outcome data, including in HIV-infected persons, are unavailable.We prospectively followed up 122 South African patients (
Esmail, Aliasgar, Limberis, Jason, Olayanju, Olatunde, Dheda, Keertan   +3 more
core   +1 more source

Adverse drug reactions in South African patients receiving bedaquiline-containing tuberculosis treatment: an evaluation of spontaneously reported cases

BMC Infectious Diseases, 2019
Background Bedaquiline was recently introduced into World Health Organization (WHO)-recommended regimens for treatment of drug resistant tuberculosis. There is limited data on the long-term safety of bedaquiline.
Jackie Jones, Vanessa Mudaly, Jacqueline Voget, Tracey Naledi, Gary Maartens, Karen Cohen   +5 more
doaj   +1 more source

A Bayesian approach to estimate the probability of resistance to bedaquiline in the presence of a genomic variant.

PLoS ONE, 2023
BackgroundBedaquiline is a core drug for treatment of rifampicin-resistant tuberculosis. Few genomic variants have been statistically associated with bedaquiline resistance.
Degefaye Zelalem Anlay, Emmanuel Rivière, Pham Hien Trang Tu, Steven Abrams, Annelies Van Rie   +4 more
doaj   +1 more source

Use of bedaquiline in spinal osteomyelitis and soft tissue abscess caused by multidrug-resistant Mycobacterium tuberculosis: A case report

Brazilian Journal of Infectious Diseases, 2022
Introduction: Spinal Tuberculosis (STB) represents between 1% and 2% of total tuberculosis cases. STB management remains challenging; the first-line approach consists of medical treatment, while surgery is reserved for patients with complications.
Andrea De Vito, Vito Fiore, Valentina Urru, Elena Bozzi, Nicholas Geremia, Elija Princic, Donatella Canu, Paola Molicotti, Riccardo Are, Sergio Babudieri, Giordano Madeddu   +10 more
doaj   +1 more source

Inhibitory effect of carvedilol on bedaquiline metabolism in vitro and in vivo [PDF]

PeerJ
Bedaquiline has recently been approved for the treatment of multidrug-resistant tuberculosis. Carvedilol is a cardiovascular medication extensively used in the treatment of heart failure and hypertension.
Qingqing Li, Wanshu Li, Jie Chen, Hangjuan Lin, Cixia Zhou   +4 more
doaj   +2 more sources